CytoAgents

Pittsburgh, PA · Founded 2018 · Privately Held (backing)

Developer of pharmaceutical drugs designed to treat cytokine release syndrome. CytoAgents is based in Pittsburgh, PA and was founded in 2018. It was valued at $52 million at its later-stage round in May 2023, the last priced event on record. It has raised $38.6 million across 2 recorded rounds; the latest was a $7 million early-stage round in May 2023.

PMV mark · valuation
$52.0M
Oct 2026
Priced at
its later-stage round
May 2023
Total raised
$38.6M
Last round
Early Stage VC
May 2023
What is CytoAgents worth?
$52.0MPrivateMarketView mark · Oct 2026

Valued at $52.0M at its later-stage round, May 2023. Nothing has traded since.

Free account
More of CytoAgents with a free account
  • ·The complete investor list: 15 names
  • ·Watch CytoAgents: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Valuation timeline

0 priced rounds · 32 daily marks since · Sep 2026 – Oct 2026
▮▮
Markrounds hold their value until the next priced eventMark, today
log scale
Post-money values unlock with a free account.Unlock the axis

Membership and data by Private Market View

CytoAgents funding history

2 rounds
DateRoundRaisedPost-money
May 2023Early Stage VC$7.0M▮
Jul 2021Early Stage VC$6.1M▮
Unlock post-money valuations

Membership and data by Private Market View

CytoAgents valuation

CytoAgents was valued at $52 million at its later-stage round in May 2023. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has CytoAgents raised?

CytoAgents has raised $38.6 million in total; 2 of its rounds are on record. The largest on record was a $7 million early-stage round in May 2023.

CytoAgents has filed 2 Form Ds with the SEC since 2021, most recently in May 2023 ($7 million sold to 23 investors).

How CytoAgents's valuation is determined

Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.

For CytoAgents, the most current credible signal sets the number and the older ones confirm it: a live secondary-market price first, then three or more recent prints, then institutional fund marks, and otherwise the last priced round, which never decays. The valuation is the last round’s post-money moved by the price change since that round, so no share count is assumed. Today it is set by its last priced round. Question about this number? Full methodology →

Frequently asked about CytoAgents

What is CytoAgents worth?
CytoAgents is valued at $52.0M as of Oct 2026. Valued at $52.0M at its later-stage round, May 2023. Nothing has traded since.
How much has CytoAgents raised?
CytoAgents has raised $38.6M in total funding across 2 recorded rounds.
When did CytoAgents last raise?
CytoAgents last raised in May 2023 (Early Stage VC), raising $7.0M.